Impedimed Ltd (IPD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Impedimed Ltd (IPD) has a cash flow conversion efficiency ratio of -1.034x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-10.53 Million ≈ $-7.45 Million USD) by net assets (AU$10.19 Million ≈ $7.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Impedimed Ltd stock valuation for the company's overall valuation and market capitalisation.
Impedimed Ltd - Cash Flow Conversion Efficiency Trend (2008–2026)
This chart illustrates how Impedimed Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Impedimed Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Impedimed Ltd ranked by their cash flow conversion efficiency. See IPD operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SILVER DOLLAR RES
F:4YW
|
-0.008x |
|
Nosa Med AB
ST:NOSA
|
-0.043x |
|
Eratex Djaja Tbk
JK:ERTX
|
0.189x |
|
Bd Multimedia
PA:ALBDM
|
0.061x |
|
Bytes Technology Ltd
LSE:BYIT
|
0.626x |
|
Ugint Co Ltd
KQ:195990
|
0.019x |
|
Pluri Inc.
NASDAQ:PLUR
|
0.347x |
|
Thunderful Group AB
ST:THUNDR
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Impedimed Ltd (2008–2026)
The table below shows the annual cash flow conversion efficiency of Impedimed Ltd from 2008 to 2026. View IPD stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$10.19 Million ≈ $7.21 Million |
AU$-20.03 Million ≈ $-14.17 Million |
-1.966x | -175.19% |
| 2025-06-30 | AU$20.50 Million ≈ $14.50 Million |
AU$-14.64 Million ≈ $-10.36 Million |
-0.715x | -63.65% |
| 2024-06-30 | AU$40.74 Million ≈ $28.83 Million |
AU$-17.79 Million ≈ $-12.59 Million |
-0.437x | -47.27% |
| 2023-06-30 | AU$60.88 Million ≈ $43.08 Million |
AU$-18.05 Million ≈ $-12.77 Million |
-0.296x | +3.39% |
| 2022-06-30 | AU$51.04 Million ≈ $36.12 Million |
AU$-15.66 Million ≈ $-11.08 Million |
-0.307x | +40.94% |
| 2021-06-30 | AU$25.51 Million ≈ $18.05 Million |
AU$-13.26 Million ≈ $-9.38 Million |
-0.520x | +26.02% |
| 2020-06-30 | AU$27.36 Million ≈ $19.36 Million |
AU$-19.22 Million ≈ $-13.60 Million |
-0.702x | +43.40% |
| 2019-06-30 | AU$15.79 Million ≈ $11.17 Million |
AU$-19.59 Million ≈ $-13.86 Million |
-1.241x | -89.40% |
| 2018-06-30 | AU$35.80 Million ≈ $25.33 Million |
AU$-23.46 Million ≈ $-16.60 Million |
-0.655x | -50.68% |
| 2017-06-30 | AU$58.80 Million ≈ $41.60 Million |
AU$-25.57 Million ≈ $-18.09 Million |
-0.435x | -65.33% |
| 2016-06-30 | AU$85.25 Million ≈ $60.32 Million |
AU$-22.42 Million ≈ $-15.86 Million |
-0.263x | +14.83% |
| 2015-06-30 | AU$34.84 Million ≈ $24.65 Million |
AU$-10.76 Million ≈ $-7.61 Million |
-0.309x | +38.57% |
| 2014-06-30 | AU$13.53 Million ≈ $9.57 Million |
AU$-6.80 Million ≈ $-4.81 Million |
-0.503x | +30.62% |
| 2013-06-30 | AU$10.59 Million ≈ $7.50 Million |
AU$-7.67 Million ≈ $-5.43 Million |
-0.724x | -6.30% |
| 2012-06-30 | AU$17.31 Million ≈ $12.25 Million |
AU$-11.80 Million ≈ $-8.35 Million |
-0.682x | -24.75% |
| 2011-06-30 | AU$20.68 Million ≈ $14.63 Million |
AU$-11.30 Million ≈ $-7.99 Million |
-0.546x | -16.93% |
| 2010-06-30 | AU$22.23 Million ≈ $15.73 Million |
AU$-10.39 Million ≈ $-7.35 Million |
-0.467x | +60.09% |
| 2009-06-30 | AU$10.07 Million ≈ $7.12 Million |
AU$-11.79 Million ≈ $-8.34 Million |
-1.171x | -94.18% |
| 2008-06-30 | AU$12.30 Million ≈ $8.70 Million |
AU$-7.42 Million ≈ $-5.25 Million |
-0.603x | -- |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more